GOODWILL IPRANDD AND OTHER INTANGIBLE ASSETS, NET (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Other intangible assets, net
Total IPR&D	$ 931,700,000		$ 931,700,000		$ 272,700,000
Finite-lived intangible assets
Intangible assets, gross	194,427,000		194,427,000		194,427,000
Other intangible assets, net	137,411,000		137,411,000		152,830,000
Amortization expense	5,200,000	5,200,000	15,400,000	15,700,000
Estimated aggregate amortization of intangible assets
Remainder of 2013	5,182,000		5,182,000
2014	20,729,000		20,729,000
2015	20,729,000		20,729,000
2016	19,449,000		19,449,000
2017	18,210,000		18,210,000
2018 and thereafter	53,112,000		53,112,000
Total	137,411,000		137,411,000		152,830,000
Patents
Finite-lived intangible assets
Intangible assets, gross	2,627,000		2,627,000		2,627,000
Less: accumulated amortization	(2,477,000)		(2,477,000)		(2,431,000)
Acquired technology rights
Finite-lived intangible assets
Intangible assets, gross	191,800,000		191,800,000		191,800,000
Less: accumulated amortization	(54,539,000)		(54,539,000)		(39,166,000)
Tedizolid phosphate
Other intangible assets, net
Total IPR&D	659,000,000		659,000,000
Bevenopran (formerly known as CB-5945)
Other intangible assets, net
Total IPR&D	78,700,000		78,700,000		78,700,000
Ceftolozane/tazobactam (formerly known as CXA-201) for HABP and VABP
Other intangible assets, net
Total IPR&D	174,000,000		174,000,000		174,000,000
Ceftolozane/tazobactam (formerly known as CXA-201) for cUTI and cIAI
Other intangible assets, net
Total IPR&D	$ 20,000,000		$ 20,000,000		$ 20,000,000